OncoMatch/Clinical Trials/NCT06994195
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer
Is NCT06994195 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including BL-B01D1 and Liposomal doxorubicin, Paclitaxel or Topotecan for epithelial ovarian cancer.
Treatment: BL-B01D1 · Liposomal doxorubicin, Paclitaxel or Topotecan — This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resistant recurrent epithelial ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Allowed: FOLR1 positivity
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Previously treated with a platinum-based regimen and confirmed to have platinum-resistant recurrence
Cannot have received: antibody-drug conjugate targeting topoisomerase I inhibitors
Exception: front line only
Front line received ADCs targeting topoisomerase I inhibitors
Cannot have received: EGFR inhibitor
Exception: front line only
Front line received ADCs targeting EGFR
Cannot have received: HER3 inhibitor
Exception: front line only
Front line received ADCs targeting HER3
Cannot have received: autologous or allogeneic stem cell transplant
Had a history of autologous or allogeneic stem cell transplantation
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
no severe cardiac dysfunction, with left ventricular ejection fraction ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06994195 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antibody-drug conjugate targeting topoisomerase I inhibitors, EGFR inhibitor, HER3 inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages